95% response to bispecific antibody in follicular lymphoma

Bispecific antibodies

Previously untreated follicular lymphoma (FL) patients who received epcoritamab with rituximab-lenalidomide (R2) had a 95% overall response rate (ORR), according to preliminary trial data.

The results of two ongoing Phase I/II clinical trials evaluating cancer immunotherapy epcoritamab, a T-cell engaging bispecific antibody, were shared at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, in Chicago, US.

A preliminary analysis of data from the EPCORE NHL-2 study, evaluating epcoritamab in combination with R2, also demonstrated a complete response rate (CRR) of 85%.

New data from the cycle 1 optimisation part of the EPCORE NHL-1 study, evaluating epcoritamab in patients with relapsed/refractory (R/R) FL, showed that cytokine release syndrome (CRS) (any grade) was reported in 49% of patients vs 66% in the pivotal cohort.

Additionally, there were no Grade 3 or higher CRS events and no reported immune effector cell-associated neurotoxicity syndrome (ICANS).

FL is the second most common form of non-Hodgkin’s lymphoma (NHL), accounting for 20-30% of all NHL cases.

“Follicular lymphoma is considered incurable and patients at all stages of disease need innovative treatment options. Our data at this year’s ASCO suggest that epcoritamab can potentially provide promising overall and complete responses for patients with follicular lymphoma, whether previously untreated or post-relapse. Importantly, we’ve also focused on reducing incidence of CRS and ICANS through optimising dosing safety of epcoritamab for patients with relapsed/refractory disease,” said Judith Klimovsky, Executive Vice President & Chief Development Officer, Genmab.

IgG1-bispecific antibody

Epcoritamab, being co-developed by Genmab and AbbVie, is an IgG1-bispecific antibody created using Genmab’s DuoBody technology and administered subcutaneously. It is designed to simultaneously bind to CD3 on T cells and CD20 on B cells and induces T-cell-mediated killing of CD20+ cells.

Epcoritamab (approved under the brand name EPKINLY in the US and Japan, and TEPKINLY in the EU) has received regulatory approval in certain lymphoma indications in several territories.

Genmab and AbbVie continue to evaluate the use of epcoritamab as a monotherapy, and in combination, in a range of haematologic malignancies, including in four ongoing Phase III randomised trials.

Diana Spencer, Senior Digital Content Editor, DDW

Related Articles

Join FREE today and become a member
of Drug Discovery World

Membership includes:

  • Full access to the website including free and gated premium content in news, articles, business, regulatory, cancer research, intelligence and more.
  • Unlimited App access: current and archived digital issues of DDW magazine with search functionality, special in App only content and links to the latest industry news and information.
  • Weekly e-newsletter, a round-up of the most interesting and pertinent industry news and developments.
  • Whitepapers, eBooks and information from trusted third parties.
Join For Free